Interleukin-2 biosimilar - Laboratorio VarifarmaAlternative Names: Ilcass; Interleukina-2 recombinante
Latest Information Update: 28 Feb 2014
At a glance
- Originator Laboratorio Varifarma
- Developer Laboratorio Pablo Cassara; Laboratorio Varifarma
- Class Adjuvants; Antineoplastics; Interleukins; Lymphokines
- Mechanism of Action Immunostimulants; Interleukin-2 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Cancer
Most Recent Events
- 10 Aug 2011 Launched for Cancer in Argentina (Parenteral)